Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.

Exact Sciences' Q3 earnings report has led to a ... Exact faces challenges with its net losses, competitive threats, and market saturation, prompting a "Hold" rating. Management remains optimistic ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

We have a Very High Uncertainty Rating on Exact Sciences. Key risks to our valuation include competitive risks related ... of our people and exacting analysis of our research processes.

November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq ... collected cohort of samples from its ASCEND 2 study. The analysis indicated an overall sensitivity of 55% in cancers without ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

(2) Represents stock-based compensation expense and 401(k) match expense. The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.